Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A new mj etf started to trade. MJUS etf as of yesterday, and we're holding #14 on their list. This etf is long term focused. They bought 13,462 shares at 75.01 cents today, but I do expect their share holdings of marimed to increase substantially. There's a download link for all of the current investments here...
https://etfmg.com/funds/mjus/
Lol. I know, silly, :), better than getting drunk though. It just seems like it's never-ending with the economic turmoil. Why the need for increased taxes on two fronts, when the easiest thing to do would be to legalize mj, then tax that on a federal level. You just can't keep on raising taxes, because it will just slow down growth. Anyways, we'll see how the next few weeks play out. It would be nice to get that pop in price upwards next month. The good news is that Marimed is addressing the marketing issue with the job adds posted the past couple of weeks, including the one for brand awareness, or whatever the exact title was.
Biden needs to be put in prison...
WTF BIDEN.... So between the proposed 39% capital gains tax for anyone making more than a million bucks, and raising the corporate tax almost back to where it was before Trump cut it to a reasonable rate, he is gong to kill the economy... OH JOY... The only silver lining with the ridiculous capital gains hike is that shorting would slow down, maybe... It really is making less sense to live in this country.... I pray neither passes... Freaking democrats... It's going to be a long road ahead for everyone now.... Better smoke it up folks... MRMD...
Best bud is the likely culprit based on the share price offered to them for their 5 million shares in the s3 form that was just posted. I'm sick of the institutional players f*#*ing around with this ticker. And no, I haven't sold. Still here, just irritated that Marimed is making more money than a few of the big boys, yet this nonsense continues because of the damn greedy f#*#ing institutional players. Just plain disgusting on their part.
Btw, to those wondering what the current price to sales range is for the sector, it's 10-20, based on what the big boys are trading at. Not 4, which is what standard blue chip tickers trade at. The cannabis sector is a growth sector, not blue chip. C'mon congress, pass the banking laws already... MRMD...
P.S. It would be nice if we had 2800 followers here, like the other board. I think ihub is more useful, but it's my opinion of course.
Thank you for sharing that information, and your honesty. As I mentioned, it seems promising for sure. At the very least, I will trade this ticker until further developments in the right direction with the revs and share structure. Atb2u...
Hello folks. I'm currently an investor in the MMJ sector (Marimed inc), and someone from the stocktwits message board there mentioned this company as an additional investment option. Anyways, this company and their business plan seems interesting, but I'm confused as to how there is a float of 24.9 million shares, yet there are 2.85 billion shares. Is the float a mistake on Ihubs stock information, and how many more shares will be added to the outstanding shares, or is the recent acquisition shares already included in the total? Also, what are the projected revenues for 2021, and how big is the company planning on growing? Nationwide, international? Any plans for uplisting past the pinksheets? I'm interested, but am concerned about the share structure and am wondering how much revenue growth is the company intending on reaching this year and beyond? I live in Massachusetts (Springfield), where hemp isn't really set up yet (and probaly won't be due to lack of land), although MJ is booming. Thanks in advance.
You have got to be kidding me. Are you really resorting to investopedia to tell you what's a good price to sales ratio????? You might as well go and join the sundial gang than. Investopedia is an absolute freaking joke used by newbies.... I will be glad to take newbie traders shares out of their hands....
Marimed is currently in discussions in Ohio and Michigan, and is also looking to expand into Pennsylvania, New Jersey, and New York. They're also looking to expand their product licensing into other markets. It's mentioned in this article where Fireman is interviewed. I seriously hope they pull it off. Cha ching Cha Ching....
https://www.newcannabisventures.com/mso-marimed-looks-to-expand-after-securing-46-million-financing/
MSO MariMed Looks to Expand After Securing $46 Million Financing
April 6, 2021 at 2:49 pm
Exclusive article by Carrie Pallardy
Exclusive Interview with MariMed President and CEO Bob Fireman
“Bigger doesn’t mean better,” according to MariMed (OTCQX: MRMD) President and CEO Bob Fireman. Cannabis MSO MariMed doesn’t have the footprint of some of its peers, but it is profitable and looking to grow. Fireman spoke with New Cannabis Ventures about the company’s current market presence, interest in M&A and bringing more attention to the company. The audio of the entire conversation is available at the end of this written summary.
A History of Organic Growth
The MariMed management team has been together for more than 10 years. Over that time, the team has built the company from the ground up, winning licenses to develop the core business. The business was financed through real estate management licensing fees, according to Fireman. Then a year and a half ago, the team made the decision to consolidate its client operating business into a public company.
The first operations rolled into the public company are in Massachusetts. MariMed owns a 135,000-square-foot manufacturing facility in New Bedford. It has developed 70,000 square feet, and it has ramped up to more than 1,000 pounds per month in the Massachusetts market. The company has a dispensary in Middleborough and two more in development. Its Betty’s Eddies, Kalm Fusion and Nature’s Heritage are top-selling brands in the state.
The Interior of a MariMed Dispensary in Massachusetts
Operations in Illinois have also been rolled into the public company. MariMed has been in the state since the inception of its medical program, and it won four licenses when the adult-use program launched. Three dispensaries are open, and the company is about to open a fourth location in Metropolis, Illinois, near the Kentucky border.
In Maryland, MariMed has developed a 180,000-square-foot facility for its client Kind Therapeutics, and it is opening a dispensary in Annapolis.
The company launched a pilot program in Delaware and exclusively ran it for two years, according to Fireman. It developed a 46,000-square-foot facility in Wilmington, and now, it is working on developing a 100,000-square-foot facility in Milford.
In Nevada, MariMed has a small cultivation operation that it is looking to expand.
A Growing Team
As an attorney and entrepreneur, Fireman has a long history of working with startups. His work with Sky Vegetables, a company focused on urban rooftop farming, led him to the cannabis space. His team members in New York introduced him to the business, and eventually, they took over a dispensary.
Fireman also got involved in the development of the Thomas C. Slater Compassion Center in Rhode Island, a medical dispensary. With the best practices learned through the initial work in the cannabis space, Fireman and his team formed the initial part of MariMed, winning licenses in Massachusetts, Maryland, Delaware, Illinois and Nevada.
MariMed’s core team includes Fireman, CFO Jon Levine and COO Tim Shaw. Levine has a background in finance and startups, as well as real estate. Shaw has in-depth experience in cannabis, helping to develop a team of people who understand genetics and growing cannabis. Fireman also highlighted Senior Vice President of Sales and Chief Product Officer Ryan Crandall, IT Director Joseph Khoury and Director Eva Selhub, MD.
The company has 277 employees, and it is looking to add more. MariMed is planning to add more people to its C-suite and launching a whole division focused on diversity.
Industry Consolidation
Last year was transformative for MariMed, according to Fireman. The company secured a long-term financial partner: Hadron Healthcare Fund. The $46 million financing facility has enabled the company to pay off all of its debt, save for bank debt and one convertible note. MariMed has also been able to clean up its balance sheet and finish expansion work, giving it increased canopy and capacity across its footprint. The recent capital infusion is also helping it to do the next roll-ups into the public company.
The company is profitable, cash-flow-positive and has a financial partner to help it expand. This makes MariMed well-positioned for M&A, according to Fireman.
While it is ready to participate in industry consolidation, the team does not want to overpay for any assets. They will likely be looking for other entrepreneurs similar to themselves who have developed licenses in certain states. Any expansion the company does will be in the service of profit and earnings for shareholders.
Markets of Interest
MariMed is considering markets like Pennsylvania, New Jersey and New York. It is also currently in discussions in Ohio and Michigan. The company also plans to grow by licensing its brands to partners in other states.
MariMed Plans to Drive Further Growth by Licensing Its Brands.
U.S. Regulatory Landscape
Following the passage of the 2018 Farm Bill, MariMed made an investment in hemp with the intention of creating a leading position in the CBD industry. Fireman ultimately sees a place for CBD and other cannabinoids in improving formulations. But, following the collapse of CBD prices, MariMed is currently focused on its cannabis business.
With potential federal legalization in the near future, Fireman expects the industry to continue becoming more mainstream with brands and direct-to-consumer strategies growing in importance. He also hopes legalization will come with some form of protection for the industry, particularly as cannabis grown in places like Colombia is much less expensive than cannabis grown in the U.S.
Access to Capital
With the company’s new long-term relationship, it has access to capital to continue its plans for growth. Fireman is now looking to tell MariMed’s story to the marketplace. The company did approximately $50 million in revenue and $16.3 million in EBITDA in 2020. He considers MariMed’s stock undervalued and hopes to reach multiples more in line with the average of its peers.
2021 Outlook
In 2020, the company’s cannabis revenue grew more than 200 percent. Now, MariMed is offering guidance for the first time, forecasting revenue of $100 million in 2021. With the opening of more dispensaries and the potential for more roll-up activity, the company could do substantially more than $100 million in revenue, according to Fireman.
MariMed has an internal review of every one of its business units. It leverages major metrics like revenue, efficiency, earnings and expenses to drive the business forward.
Last year, the COVID-19 pandemic posed a major challenge in the industry, one that led to innovations in home delivery and curbside pick-up. This year, MariMed is looking to continue its growth with the addition of more dispensaries, increased capacity and brand expansion through licensing partnerships.
Fireman is hopeful that MariMed’s management team, genetics, products and access to capital are powerful differentiators that will drive the company’s success in 2021.
To learn more, visit the MariMed website. Listen to the entire interview:
Based on the volume, it looks more like traders following the longer term chart patterns. Historically speaking, for some strange reason, the company would release better than expected annual results, and the market takes a nose dive instead. I was hoping that wasn't going to happen, but it did as we can see. It just means that we get the huge spike in price around the time of Q1 2021 report (May/June). I'm going to continue to accumulate as much shares as possible until such move. The longer she churns at these levels, the higher the price moves when the mm's and larger players finally decide to play nice... MUNCH MUNCH MUNCH.... MRMD....
The average price to earnings ratio for the mj sector as of lately has been in the 10-20 range. 10 x 50.9 million= 509 million market cap, and 20 x 50.9 million= 1.018 billion market cap. Take the market cap, divide it by the current os of 320 million, and you have a price range of $1.59-$3.18. We should be on the higher end of that range though, because of the serious revenue growth potential.
The feds need to get that damn banking act passed already. I've had $2500 bucks that was transferred from another account put on hold for 4 days now. This is a total crock of shit that there are still holds from trading mj stocks for several days. Oh well, guess I have to wait till tomorrow to add more shares to my total...
We also have an eps of a penny per share, yay. Not to shabby, considering the huge mess they had to clean up, no thanks to Gencanna. 50.9 million bucks, with a profit of $2.07 million. Keep it up guys, the sky's the limit.... MRMD...
Details about Hedron investment, page 24:
Dispensary number two for Massachusetts will be in Beverly, and dispensary number four for Illinois will be in Metropolis. This is where those funds come in handy.
I'm buying more tomorrow. Adding a couple thousand shares more tomorrow myself, which would put me at 50 thousand shares. I wasn't planning on ever going this heavy. But then Gencanna happened, and had to decide if I wanted to average down from 83 cents or not. It was a no brainer for me, because of their success on the mj side of Marimed. Betty's eddies is absolutely delicious. I haven't tried nature's heritage yet, but I will this weekend at Insa Springfield or Easthampton (depending on available merchandise). Anyway's, even though being on the titanic was quite a horrible experience, I'm still a firm believer of the company as a whole. Nasdaq bound baby.....
From the 8k that was just released recently. It should be in the first paragraph of item 1.01 (Entry into a Material Definitive Agreement).
This I like...
Next Monday, after hours...
That does seem funny. Although they clearly exist, since we do have those awards won for Betty's Eddies, and I believe Nature's Heritage has one as well. Maybe they hope to build 300,000 more, which is certainly doable now with the additional funds received, as well as cleaning up their balance sheet.
I certainly hope they plan on expanding their product lines into more states asap. The upgrade in kitchen production will certainly help in the states where they operate physically, but we also need distribution deals in other states. This might not be necessary, however, if the federal laws were to change. Decriminalization is the first big step in helping to remove the tons of red tape legal mj businesses go through to become MSO's.
It was an overall market sell off over fear of rising rates. The good news is that the biggest earnings season is arriving upon, which is the annual report followed shortly by Q1 report of the new fiscal year. Tax season happens at the same time, and there will be your typical boost. Although this tax season should see a big boost in overall market prices, all thanks to the stimulus recovery credit and additional credits, meaning refunds in the thousands. And if you have a family, or dependants, it would be much more. May 1st I believe is the Q1 report, but I might be wrong there.
Hello everyone from little ole Massachusetts. First time poster in this room, and I thought I share some good news on Marimed's comeback story. Marimed (MRMD) almost went under after a series of poor investments, blindly giving money to crooks, including the now infamous giant Genncanna. Anyways, the company survived because of it's growing core marijuana business, which reported it's first profitable quarter just recently (Q3 2020). They've also just received one of their largest investments, as mentioned in this article that was posted today. Share structure is 318 million, with the annual report due this month.
www.marimedinc.com
https://www.newswire.ca/news-releases/marimed-secures-new-funding-from-long-term-capital-partner-897441206.html
Cision Canada
FR
MariMed Secures New Funding from Long-Term Capital Partner
NEWS PROVIDED BY
MariMed Inc.
Mar 02, 2021, 16:05 ET
Capital Infusion to Strengthen Balance Sheet and Provide Funding for Strategic Acquisitions
$46 Million Dollar Financing Facility to Accelerate Company Growth Strategy
NORWOOD, Mass., March 2, 2021 /CNW/ - MariMed, Inc. (OTCQX: MRMD) (the "Company" or "MariMed"), a leading multi-state cannabis operator focused on health and wellness, today announced the closing of a $46 million financing facility with Hadron Healthcare Fund ("Hadron") pursuant to the terms of a Securities Purchase Agreement ("SPA").Today's initial funding of $23 million, will be used to repay substantially all of the Company's long-term debt other than mortgage-backed loans as well as to upgrade and expand MariMed's owned and managed cannabis facilities. The balance of the committed funds will be available for MariMed to continue executing on its strategic plan and complete the consolidation of other state cannabis businesses into MariMed.
"We are thrilled to have been selected by Hadron as their preferred partner to complete this strategic investment in the US MSO sector," said Bob Fireman, CEO of MariMed. "This financing is a substantial recognition of both the Company's position in the industry as well as the strength and track record of our management team. This infusion of capital comes at a key inflection point for MariMed and will not only further strengthen our balance sheet, but also enable us to complete targeted acquisitions and strongly position us to act on other attractive opportunities for accelerated growth as the cannabis industry continues to evolve."
MariMed intends to utilize this capital investment to position itself as one of the leading vertically integrated US multi-state cannabis operators. The Company expects to expand its cultivation capacity to increase cannabis production and implement automated technologies and specialized equipment to improve the efficiencies in the Company's production labs and kitchens in order to produce greater volumes of MariMed's portfolio of proprietary brands and infused products. MariMed's executive leadership team has significant experience and an extensive track record of executing in the cannabis industry. To date, the MariMed team has successfully won 17 cannabis licenses in multiple states for itself and on behalf of its clients and has developed over 300,000 square feet of state-of-the-art, regulatory compliant cultivation, production and dispensing facilities.
"When we looked at the history of the MariMed and its management team, we strongly felt MariMed was the best opportunity for our continued interest and investment into the United States MSO space," said Marco D'Attanasio, CIO of Hadron Capital (Cayman) Ltd, the investment manager of Hadron Healthcare Fund. "MariMed's strong brand presence, operational excellence, and management track record, supported by our capital investment, will give them the best tools to continue to execute and drive stockholder value. We view MariMed assets and revenue as a platform to build a top professional and profitable MSO in the cannabis industry. We look forward to working with them as a long-term partner."
Transaction Details
The SPA provides for the sale of up to $46 million of Series C Convertible Preferred Shares of the Company. At today's initial closing, Hadron purchased $23 million of Units for $3.70 per Unit. Each Unit consists of one share of Series C Preferred Stock and a Common Stock purchase warrant. Each share of Series C Preferred Stock is convertible, at Hadron's option, into five shares of Common Stock and each warrant is exercisable, at an exercise price of $1.087 per share, for one-half of a share of Common Stock for each conversion share (2 ½ warrants shares per Unit). The balance of the committed funds (up to $23 million) will be issued on the same terms as the securities issued today and will be available for MariMed to complete the consolidation of other state cannabis businesses units into MariMed. In addition, if Hadron exercises all of the warrants for cash, MariMed will receive additional proceeds of approximately $34 million. Beacon Securities Limited introduced the parties to the transaction.
About Hadron Capital (Cayman) Ltd
Hadron Capital (Cayman) Ltd is an independent investment manager with global reach that was founded in 2004. Hadron has a track record of strong returns and has won multiple performance awards over the years. Hadron was an early investor in some of the largest multi-state operators in the sector and its US cannabis investment portfolio is valued at over US $300 million. Hadron's investment philosophy is strongly based on bottom-up, thorough and deep analysis. Hadron works with companies to unleash value and acts as a long-term financial partner and provider of capital for their portfolio companies.
About MariMed
MariMed Inc., a multi-state cannabis operator, is dedicated to improving the health and wellness of people through the use of cannabinoids and cannabis products. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units, keeping it at the forefront of cannabis science and innovation. Proprietary formulations created by the Company's technicians are embedded in its industry-leading products and brands, including Betty's Eddies™, Nature's Heritage™, Bourne Baking Co., and Kalm Fusion™. For additional information, visit marimedinc.com.
Important Caution Regarding Forward-Looking Statements:
This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.'s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events, including estimates and projections about its business based on certain assumptions of its management, including those described in this release. These statements are not guaranteeing of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement, and changes in the economic environment. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned, "estimated," "preparing," "potential," "expected," "looks" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.
All trademarks and service marks are the property of their respective owners.
SOURCE MariMed Inc.
For further information: Company Contact - MRMD, Jon Levine, CFO, MariMed Inc.; Investor Relations: Rob Kelly, Mattio Communications, ir@mattio.com; Media Relations: Patrick Martin, Mattio Communications, marimed@mattio.com
I seriously hope they do just that. I agree that it would have the best impact on price action.
Wowsas... This is literally one of the biggest investments someone has put into the company to date. I would be shocked if we didn't break a dollar... I can't wait for the annual report to come out for more details on this and what else has been happening behind the scenes this past year... MRMD...
It seems like they're still favoring decriminalization, expungement of records, and are ok with medical mj, just not recreational yet. It's not the first time she and other politicians have flipped flopped on mj in general, and it won't be the last time.
That second half of the year should be profitable, and is hopefully enough to make the year profitable. I'm curious to see what their guidance would be like with the report.
They moved it up to March of this year, as stated in the year end update from a month ago. Here's the link to the article.
https://www.globenewswire.com/news-release/2021/01/19/2160623/0/en/MariMed-Issues-2020-Year-End-Shareholders-Update-Letter.html
...
Maryland is one of Marimed's strongest performers at the moment, and it would make perfect sense to expand into neighboring Virginia...
https://www.politico.com/news/2021/02/27/virginia-legalizes-marijuana-471840
Virginia joins 15 other states in legalizing marijuana
Virginia is the 16th U.S. state to pass an adult-use marijuana legalization law, though sales would not start until 2024.
A marijuana plant is visible at a medical marijuana dispensary.
A marijuana plant is visible at a medical marijuana dispensary. | Julio Cortez/AP Photo
By MONA ZHANG
02/27/2021 08:21 PM EST
Updated: 02/28/2021 10:19 AM EST
The Virginia Legislature approved adult-use marijuana legalization Saturday in a historic vote marking the first state in the Old South to embrace full legalization.
The House passed the measure in a 48-43 vote, and the Senate approved it in a 20-19 vote. Not a single Republican voted for the bill in either chamber.
Advertisement
"This, to me, is a justice bill," Del. Charniele Herring, a sponsor of the legalization bill and the Democratic majority leader, said on the floor. "While it has flaws and it is not the perfect bill ... I think this moves us a step in the right direction."
The vote came after a conference committee struck a deal on Saturday to reconcile different versions of the bill that passed in both chambers earlier this month.
The impact: Virginia is the 16th U.S. state to pass an adult-use marijuana legalization law, though sales would not start until 2024. Only two other states — Illinois and Vermont — have passed legislation to legalize, tax and regulate recreational marijuana through the legislature.
The move puts pressure on neighboring states such as Maryland, where an adult-use legalization bill got its first hearing this month. New Jersey also recently enacted legalization, after voters overwhelmingly backed a referendum in November.
Advertisement
What’s next: Democratic Gov. Ralph Northam has championed legalization as a racial justice issue.
Under the compromise legislation, marijuana possession would not become legal until January 2024, when regulated sales are scheduled to start. The state would start setting up a marijuana regulatory agency this July.
The background: The state decriminalized marijuana last year during a special session to address criminal justice reform. Virginia’s medical marijuana program is just getting off the ground, and lawmakers passed a bill this session that would expand the program to allow marijuana flower products.
Northam endorsed legalization in November and urged lawmakers to pass his proposal during his state of the state address. The legislation was based on two extensive studies on the issue: a report from his administration and another from the nonpartisan Joint Legislative Audit and Review Committee.
Advertisement
The bills moved quickly through the chambers during a short, 30-day session, which Northam extended with a special session of 16 days. Lawmakers tackled thorny issues such as how to prevent large corporations from taking over the marijuana market, and how to handle automatic expungements of marijuana offenses when the criminal justice system lacks the technology to do so.
Opponents of marijuana legalization pointed to public health concerns such as youth use and impaired driving, as well as tobacco giant Altria’s lobbying on the issue. Altria purchased a $1.8 billion stake in Canadian cannabis company Cronos Group in 2018.
Marijuana advocates pointed to the harms of the disproportionate enforcement of marijuana offenses in communities of color. The bill contains robust social equity provisions, including prioritizing business licenses for individuals deemed to have been disproportionately impacted by criminal enforcement, which dissuaded some otherwise supportive Republicans from voting for the bill.
“Initially, I was supportive of the approach that is encompassed in this bill,” said GOP Senate Minority Leader Thomas Norment during floor debate. Norment pointed to his advocacy of the marijuana decriminalization bill that passed last year.
“I just don't accept this social equity set aside on the issuance of licenses. We don't do it for alcohol, we don't do it for other matters,” he said.
The details: The bill would allow adults over 21 to possess up to 1 ounce of marijuana. Home cultivation of up to four plants per household would be allowed under the bill.
The bill sets a 21 percent excise tax on marijuana and allows municipalities to add an additional 3 percent tax on retailers on top of existing sales taxes. Marijuana tax revenues would be used to fund pre-K education, substance use disorder treatment programs and other public health initiatives. A portion of revenues would also go toward a Cannabis Equity Reinvestment Fund, which would provide resources such as scholarships and workforce development for communities disproportionately impacted by drug enforcement.
Vertical integration would be allowed in limited circumstances to grandfather in medical cannabis producers and industrial hemp processors. Micro-businesses would be allowed to vertically integrate as well.
CORRECTION: An earlier version of this report misstated the number of plants allowed for home cultivation. The bill would allow for home cultivation of up to four plants per household.
FILED UNDER: VIRGINIA, RALPH NORTHAM, MARIJUANA LEGALIZATION
And it's a respectable choice. She's a rare one indeed. Which is why I'm sorta surprised with the funny games on the stock side. It would be nice if the games would stop,but than again, there's also no harm in profiting along the way. Although I'm personally looking to diversify again, but just a handful, this time for the longer haul. I live in Massachusetts and intend on starting with the legit Massachusetts companies first. Marimed being my first choice, because they are being proactive with their host communities, plus they saved jobs from leaving New Bedford. I look for actions like that when looking at new investment options.
A merger /acquisition might be possible in a couple of years, after several profitable quarters, and expansion as well. If that were to happen, it wouldn't be with questionable companies, like at least half of the Canadian operators, but a respectful company instead (Curaleaf?). Although, I was under the impression that Fireman is looking to retire to Vermont, and was looking for a suitable replacement. He mentioned that a while back in one of his many interviews. I don't remember when exactly, but I believe that's what he stated. The July 2017 filings also include Marimed's summarized business plan. Anyways, as annoying as this is currently with the price action, it'll change again for the better soon. Just make sure to trade at least part of what you have then. I will begin trading then as well. ATB2U...
Wowsas.... What happened????? Why are the mm's so obssessed with f$*%ing around with the sector. Need I remind everyone that this is a real industry that is creating jobs, as well as investment opportunities. This is not some shell company is all I am saying. Anyways, annual report is just around the corner.
Hopefully the sector will be green tomorrow. All I saw was red across the board. I wonder how much of that volume is from the reddit crowd, if they're still around. Serious investors wouldn't sell this particular stock right before filings. Who knows with the recent action. Anyways, I'm looking forward to the rest of the year, and beyond. MRMD...
The 80-90 cent range is a good support level to bounce off of. A rough double would put us next at $1.60-$1.80, but we might even pull a tripple bagger+ (depending on circumstances) with the upcoming annual report. A tripple from the current support levels would be $2.40-$2.70. Again, this is all just a guess based on the pattern created over the past 3 months, and fundamentals.
Curaleaf is overshadowing it right now, and rightfully so. Curaleaf is much older than Marimed, and is where I see us being in a few years time. Break that first $100 million, and the bigger sharks start to bite, and we show the entire investment world that Marimed is finally one of the big boys. Just my opinion, of course. As for the upcoming annual report, I'm guessing $50 million roughly.
Aerovox stayed in New Bedford because of Marimed. The company was about to leave the city, but then Marimed bought the building that Aerovox is located in, and worked out a deal that saved the company and people kept their jobs.
Marimed did a reverse merger to transition from a private company to a publicly trade company. That company was worlds online (wddd), and Thomas Kindrin was the guy behind that. This was done in July 2017. There should be some filings there dated around that time.
The crash down from $300 was even harder. I witnessed that stock hit $300 for a flash, and then the twin towers came down. I'm just glad the sector is alive again. I'm definitely going to start trading again after financials. I want to flip a few times here, before I start diversification again.
Finally we break a dollar. Now that should catch new eyes by technicals, hopefully. And all of this before the annual report is even better for everyone overall. Obviously there'll be profit taking along the way. However, there is far more eyes watching now versus 2018, so this should be a very interesting year....
A great close, and having a new 52 week high in today's volume is even better. In fact, many tickers in the sector are up tremendously today. Wowser. It would be nice if the sector returned to their previous p/e levels (400 p/e), we'll see.
That would do wonders indeed, but is not necessary for bringing more attention to this stock. As great as the management team has been in cleaning up their balance sheet, they really suck at promoting their work. Fireman he is not when it comes to presentation. Just saying.